DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Keratol Nail Gel (Urea Topical) - Summary

 
 



SUMMARY

DESCRIPTION: KeratolTM 45 Nail Gel, is a keratolytic emollient, which is a gentle, yet potent, tissue softener for nails and/or skin.   Each gram of KeratolTM 45 Nail Gel contains 45% Urea, camphor, edetate disodium, eucalyptus oil, hydroxyethyl Cellulose, menthol, propylene glycol and purified water.

Keratol is indicated for the following:

For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly when healing is retarded by local infection, necrotic tissue, fubrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails.


See all Keratol Nail Gel indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Keratol Nail Gel (Urea Topical)

Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream. [2011.12]
Abstract Background: Ichthyoses are genetic disorders of keratinization which are uncomfortable due to their conspicuous scaling, itching and cosmetic problems.Further studies with larger sample sizes are needed for the evaluation of safety and tolerability of urea 10% lotion in this clinical setting.

Clinical evaluation of 35% urea in a water-lipid-based foam containing lactic acid for treatment of mild-to-moderate xerosis of the foot. [2011.03]
BACKGROUND: We evaluated 35% urea in a water-lipid-based foam delivery system containing lactic acid in participants with mild-to-moderate xerosis of the foot... CONCLUSIONS: Thirty-five percent urea in a water-lipid-based foam delivery system containing lactic acid can be an appropriate treatment option for mild-to-moderate xerosis of the foot.

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. [2010.12.10]
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS... CONCLUSION: These data do not support the efficacy of a ULABTKA cream for preventing HFS symptoms in patients receiving capecitabine.

Efficacy and safety of a new topical keratolytic treatment for localized hyperkeratosis in adults. [2010.12]
BACKGROUND: Palmoplantar keratoderma (PPK) is a heterogeneous group of skin disorders characterized by symmetrical diffuse or patchy areas of hyperkeratosis on the palms and soles. This study aimed to evaluate the efficacy and safety of a topical keratolytic treatment for localized hyperkeratosis... CONCLUSION: This topical keratolytic treatment represents a valuable first-line option for mild to moderate hyperkeratosis.

Efficacy and safety of a new topical keratolytic treatment for localized hyperkeratosis in adults. [2010]
topical keratolytic treatment for localized hyperkeratosis... CONCLUSION: This topical keratolytic treatment represents a valuable first-line

more studies >>

Clinical Trials Related to Keratol Nail Gel (Urea Topical)

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function [Recruiting]
This diagnostic study will be performed to investigate the performance of the urea cycle in healthy subjects, asymptomatic carriers of Urea Cycle Disorders (UCD) mutations and subjects with genetically proven urea cycle disorders. The ureagenesis rate will be measured by 13C incorporation assay, a method for in vivo measurement of urea cycle performance with stable isotopes.

Sorafenib-induced Hand- Foot Skin Reaction Treatment [Recruiting]

Neurologic Injuries in Adults With Urea Cycle Disorders [Recruiting]
Urea cycle disorders (UCDs) are a group of rare inherited metabolism disorders. The purpose of this study is to evaluate how UCD-related neurologic injuries affect adults with one of the most common types of UCD.

Homeopathic Ear Drops for Otitis Media Study [Recruiting]
The purpose of this study is to determine if a commercially available homeopathic ear drop

preparation is effective in reducing symptoms in children 6 months - 11 years old with acute

otitis media in whom the health care provider has recommended that antibiotics not be immediately administered. A total of 150 study patients with otitis media will be randomized to receive homeopathic ear drops, or no ear drops, in addition to receiving standard care. It is postulated that children using the ear drops will have more rapid resolution of symptoms and need fewer antibiotics than those randomized to not receive the ear drops.

Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis [Recruiting]
Background:

- Tuberculosis is a disease of the lungs caused by the bacteria Mycobacterium

tuberculosis (M. tuberculosis). The most popular and least expensive tool used to detect the presence of the tuberculosis bacteria is called sputum smears, which is a lab test used to look for bacteria in the sputum via a microscope. However, the test's results are not always accurate, and the test cannot determine if the bacteria will be resistant to standard tuberculosis treatments. The most sensitive test currently available is called sputum culture, in which a sputum sample is used to check for the growth of tuberculosis bacteria. However, this test takes at least a month to produce accurate results, and requires expensive equipment that is not available in many countries where M. tuberculosis is found.

- The urea breath test (UBT) has been used to detect infection with Helicobacter pylori,

a bacteria associated with stomach ulcers, by testing individual breath samples. Researchers are interested in determining whether breath samples can also be used to detect the presence of M. tuberculosis in the lungs of subjects with tuberculosis, and to see if tuberculosis treatments are successful.

Objectives:

- To assess the sensitivity and specificity of urea breath testing in the diagnosis and

treatment response of pulmonary tuberculosis.

Eligibility:

- Individuals at least 18 years of age who either have been diagnosed with tuberculosis

or are healthy volunteers with no past history of tuberculosis.

- The study will be conducted in Bamako, Mali.

Design:

- This study will involve three groups: two pilot groups of individuals who have already

been diagnosed with tuberculosis, and a primary study group of both healthy volunteers and individuals who have been diagnosed with tuberculosis.

- Participants will be screened with a physical examination and medical history, as well

as blood, sputum, stool, and urine samples.

- First pilot group (one visit):

- Participants should not eat, drink, or smoke for at least 1 hour prior to the UBT test.

- Participants will provide a baseline exhaled air sample, and then will receive the UBT

test, which involves a dose of Pranactin(Registered Trademark)-Citric dissolved in water. Additional exhaled air samples will be collected at eight time points (10, 20, 45, 60, 90, 120, 180, and 240 minutes after the dose).

- Second pilot group (one or two visits):

- Participants should not eat, drink, or smoke for at least 1 hour prior to the UBT test.

- Participants will provide a baseline exhaled air sample, and then will receive the UBT

test. Half of the participants will receive a dose of bismuth (Pepto-Bismol) prior to collection of air samples to see how this affects the results of the UBT test. Additional exhaled air samples will be collected at three time points specified by the study researchers.

- On the following day, participants will return for a second visit to provide three more

exhaled air samples.

- Primary study group (five visits for participants with tuberculosis, two visits for

healthy volunteers):

- All participants will have two visits, following the procedures given for the second

pilot group. Half will receive a dose of bismuth prior to collection of air samples.

- Participants with tuberculosis will have three additional visits (days 6, 10, and 16

following the first study visit) to provide additional sputum and exhaled air samples to monitor the progress of tuberculosis treatment.

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014